Article Information
History
- May 16, 2017.
Article Versions
- Version 1 (May 5, 2017 - 16:05).
- You are currently viewing Version 2 of this article (May 16, 2017 - 11:42).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Giordano de Guglielmo1,
- Marsida Kallupi1,
- Matt Pomrenze2,
- Elena Crawford1,
- Sierra Simpson1,
- Paul Schweitzer1,
- George F. Koob3,
- Robert O. Messing2 and
- Olivier George1,*
- 1Department of Neuroscience, The Scripps Research Institute, La Jolla, CA 92037 USA
- 3Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA
- 2National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
- ↵*Corresponding author: Dr. Olivier George, Department of Neuroscience, The Scripps Research Institute, 10550 North Torrey Pines Road, SP30-2400, La Jolla, CA 92037, USA. Tel: +1 858 784 7102. Fax. +1858 784 7405. E-mail: ogeorge{at}scripps.edu